Detalles de la búsqueda
1.
Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings.
Qual Life Res
; 29(10): 2651-2660, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32405921
2.
Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices.
Future Oncol
; 15(5): 459-471, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30251550
3.
High-dose hemodialysis versus conventional in-center hemodialysis: a cost-utility analysis from a UK payer perspective.
Value Health
; 18(1): 17-24, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25595230
4.
A global overview of renal registries: a systematic review.
BMC Nephrol
; 16: 31, 2015 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-25886028
5.
The financial impact of increasing home-based high dose haemodialysis and peritoneal dialysis.
BMC Nephrol
; 15: 161, 2014 Oct 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-25278356
6.
Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States.
J Med Econ
; 24(1): 816-827, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34126842
7.
Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
J Med Econ
; 23(2): 132-138, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31750751
8.
An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma.
J Drug Assess
; 8(1): 135-145, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31489255
9.
Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: A retrospective, community oncology-based cohort study (A STROBE-compliant article).
Medicine (Baltimore)
; 98(28): e16328, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31305421
10.
Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study.
Medicine (Baltimore)
; 98(30): e16542, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31348273
11.
Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States.
J Manag Care Spec Pharm
; 25(8): 869-877, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30945965
12.
Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment.
Cancer Nurs
; 42(1): E52-E59, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-29076867
13.
Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
J Med Econ
; 22(10): 981-993, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31012765
14.
Factors associated with immunotherapy selection in patients with advanced melanoma.
Immunotherapy
; 10(16): 1361-1369, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30407098
15.
Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
Medicine (Baltimore)
; 97(31): e11736, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30075584
16.
Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.
PLoS One
; 13(11): e0206370, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30408065
17.
Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
J Immunother
; 41(2): 86-95, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29252916
18.
Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.
Patient Prefer Adherence
; 11: 1389-1399, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28860722
19.
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.
Pharmacoeconomics
; 35(8): 831-844, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28620848
20.
Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
J Manag Care Spec Pharm
; 23(2): 184-194, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28125365